These results suggested that pancreatic cancer patients with all stage (Figure 2B,p=0.0136) and I/II stage (Figure 2C,p=0.0257) in the ERCC3 high group had a shorter survival rate. This evidence concerns the gene ERCC3 and pancreatic neoplasm.